Alector, a Phase 1 biotech developing therapies for neurodegeneration, raised $176 million by offering 9.3 million shares at $19, the midpoint of the $18 to $20 range. Alector plans to list on the Nasdaq under the symbol ALEC. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as lead managers on the deal.
